Regeneron’s Libtayo shows response rate in line with Keytruda’s in first-line NSCLC

Interim data from a Phase III study showed that the response rate to Regeneron’s Libtayo among first-line lung cancer patients was comparable to the rate in the label of competing PD-1 inhibitor Keytruda. If upcoming Libtayo data show a survival benefit and the drug gains a label expansion,

Read the full 489 word article

User Sign In